Pulmonx Corp (LUNG) income statement
LUNGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3044% below fair value
$2.69−0.04 (-1.65%)
Close on Nov 18, 2026Market cap $115.53MP/E –Yield –
Pulmonx Corp income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 77.1%
- Operating margin
- -53.0%
- Net margin
- -55.0%
- Return on equity, FY2025
- -77.2%
Financial strength
- Current ratio
- 4.32
- Debt to equity
- 0.96
- Debt to assets
- 32.7%
- Cash to current liabilities
- 273.7%
Valuation
- P/E ratio
- –
- Price to sales
- 1.32
- Price to book
- 2.95
- Dividend yield
- –
See a number that looks wrong?